Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

Published:2010-03-20 Issue:1 Volume:67 Page:57-67
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Reece Donna E.,Sullivan Dan,Lonial Sagar,Mohrbacher Ann F.,Chatta Gurkamal,Shustik Chaim,Burris Howard,Venkatakrishnan Karthik,Neuwirth Rachel,Riordan William J.,Karol Michael,von Moltke Lisa L.,Acharya Milin,Zannikos Peter,Keith Stewart A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-010-1283-3.pdf

Reference30 articles.

1. Millennium Pharmaceuticals Inc. (2008) VELCADE® (bortezomib) for Injection. Prescribing information. Cambridge, MA, USA; Issued June 2008, Rev 9

2. Janssen-Cilag International NV (2009) VELCADE® (bortezomib). Summary of product characteristics, Beerse, Belgium

3. Ciechanover A, Schwartz AL (1998) The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 95:2727–2730

4. Boccadoro M, Morgan G, Cavenagh J (2005) Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 5:18

5. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4:349–360

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy Release From Bortezomib-Impregnated Polymethylmethacrylate-Coated Intramedullary Nails: A Novel In Vitro Study for a Local Chemotherapy Delivery Device;Cureus;2024-07-09

2. Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics;Frontiers in Endocrinology;2024-05-08

3. In Vitro Low-Bortezomib Doses Induce Apoptosis and Independently Decrease the Activities of Glutathione S-Transferase and Glutathione Peroxidase in Multiple Myeloma, Taking into Account the GSTT1 and GSTM1 Gene Variants;Genes;2024-03-21

4. Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome;Clinical Pharmacokinetics;2023-04-18

5. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy;Current Problems in Cardiology;2023-03